SMO and osteosarcoma: These data are in keeping with previous observations that Hh signaling pathway components IHH, PTCH1, SMO, GLI1 and GLI2 are expressed in human osteosarcoma, and that IHH and GLI2 overexpression is associated with poor patient outcomes [13, 14, 16, 24].